Condition

NRG1 Fusion

ClinicalTrials.gov condition label

Clinical trials4

Recruiting0

Common interventions3

Lead sponsors shown4

Clinical trials

4 shown

Integrated Genomics in Oncogene-driven NSCLC With Acquired ResistanceNCT07122882 · 2025-09-01

ENROLLING_BY_INVITATION

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene FusionsNCT03805841 · 2019-03-13

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)NCT02912949 · 2015-01-01

ACTIVE_NOT_RECRUITING

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorNCT04100694

APPROVED_FOR_MARKETING

Common interventions

MCLA-128DRUG1 tarloxotinib bromideDRUG1 zenocutuzumab (MCLA-128)DRUG1

Leading sponsors

Chang Gung Memorial Hospital1 Merus B.V.1 Partner Therapeutics, Inc.1 Rain Oncology Inc1

Trial status mix

ACTIVE_NOT_RECRUITING1

APPROVED_FOR_MARKETING1

ENROLLING_BY_INVITATION1

TERMINATED1

Phase mix

PHASE22

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.